Wave Life Sciences Ltd. (WVE) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary indicates a mix of positive and cautious elements. While there are promising developments in product pipelines and strategic plans, there are also uncertainties, particularly in the obesity program and AATD study. The Q&A highlighted management's avoidance of specifics, which may raise concerns. No strong catalysts like partnerships or record revenues were mentioned, and the strategic plan lacks immediate financial impact. The absence of market cap data limits assessment of stock sensitivity, but overall sentiment leans towards neutral given the balanced positives and uncertainties.
Key Financial Performance
Revenue $7.6 million for Q3 2025, compared to negative $7.7 million in Q3 2024. The year-over-year increase was due to the timing of revenue recognized under the collaboration agreement with GSK.
Research and Development Expenses $45.9 million in Q3 2025, compared to $41.2 million in Q3 2024. The increase was primarily driven by the advancement of the INHBE program, RNA editing programs, and compensation-related expenses, including share-based compensation.
General and Administrative Expenses $18.1 million in Q3 2025, compared to $15 million in Q3 2024. The increase was primarily related to share-based compensation and other external expenses.
Net Loss $53.9 million for Q3 2025, compared to $61.8 million in Q3 2024. The decrease in net loss was due to increased revenue and controlled expenses.
Cash and Cash Equivalents $196.2 million as of the end of Q3 2025, compared to $302.1 million as of December 31, 2024. The decrease was due to operational expenses, partially offset by $72.1 million in ATM proceeds and committed GSK milestones post-quarter-end.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
WVE-007: Demonstrated significant and durable activin E reductions in clinical trials, showing potential for meaningful weight loss and prevention of rebound weight gain. Positioned as a maintenance therapy for obesity with once or twice yearly dosing. Clinical trial data from over 100 participants expected in H1 2026.
WVE-006: Achieved key treatment goals for AATD, including restoring physiological AAT production. Demonstrated durable effects and potential for monthly or less frequent dosing. Data from ongoing trials expected in Q1 2026.
WVE-008: Advanced as a clinical candidate for PNPLA3 I148M liver disease, targeting a population of 9 million in the U.S. and Europe. Clinical planning underway with CTA submission expected in 2026.
WVE-N531: Demonstrated significant improvement in muscle health and time to rise in DMD patients. IND submission for accelerated approval expected in 2026.
WVE-003: Preparing for Phase II/III study in HD, showing potent and durable mutant Huntington reductions. IND application for the study expected in H2 2025.
Obesity market: WVE-007 received significant attention at Obesity Week, highlighting its potential as a non-incretin treatment for obesity with positive engagement from stakeholders.
AATD market: WVE-006 represents a paradigm shift from weekly IV therapies, addressing the root cause of AATD with a convenient subcutaneous dosing.
PNPLA3 I148M liver disease market: WVE-008 targets a large unmet need with no approved medicines addressing this biology, focusing on a population at high risk of liver disease.
Financial performance: Revenue for Q3 2025 was $7.6 million, a significant increase from the prior year. Net loss reduced to $53.9 million from $61.8 million in the prior year. Cash runway extended into Q2 2027 with additional ATM proceeds and GSK milestones.
R&D investment: Increased R&D expenses driven by advancements in INHBE and RNA editing programs.
Pipeline advancement: Rapid progress in RNAi and RNA editing programs, with multiple clinical and preclinical advancements.
Collaborations: Ongoing collaboration with GSK contributing to financial stability and operational progress.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Risks: The company acknowledges that forward-looking statements are subject to several risks and uncertainties, which could cause actual results to differ materially. This includes potential regulatory hurdles for their clinical trials and product approvals.
Financial Risks: The company reported a net loss of $53.9 million for Q3 2025, with a significant decrease in cash and cash equivalents from $302.1 million at the end of 2024 to $196.2 million. While additional funding has extended the cash runway into Q2 2027, future milestones and payments under collaborations are not guaranteed.
Clinical Development Risks: The success of the company's pipeline, including WVE-007, WVE-006, and WVE-008, depends on achieving clinical milestones. Delays or failures in clinical trials, such as INLIGHT or RestorAATion-2, could adversely impact the company's strategic objectives.
Market and Competitive Risks: The company faces competitive pressures in the obesity, AATD, and liver disease markets. For example, WVE-007 aims to compete with existing GLP-1 therapies, and WVE-006 seeks to replace weekly IV augmentation therapies. Failure to demonstrate superior efficacy or convenience could limit market adoption.
Operational Risks: The company is advancing multiple programs simultaneously, which could strain resources and operational capacity. Any mismanagement or delays in these programs could impact overall performance.
Economic and Funding Risks: The company is reliant on collaborations, such as with GSK, for funding and milestone payments. Economic uncertainties or changes in partnership dynamics could affect financial stability.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
WVE-007 (INHBE GalNAc siRNA): The company plans to deliver data on over 100 participants from clinical trial sites in Europe and the U.S. in the first half of 2026. Early impact of INHBE reduction at 3 months in the 240-milligram cohort will be assessed this quarter. Six-month follow-up data from the 240-milligram cohort and 3-month follow-up data from the 400-milligram cohort will be available in Q1 2026.
WVE-006 (GalNAc RNA editing oligonucleotide for AATD): Dosing is ongoing in the 400-milligram multi-dose cohort, with data expected in Q1 2026. Single and multi-dose data from the 600-milligram cohort will be delivered in 2026.
WVE-008 (GalNAc-conjugated RNA editing program for PNPLA3 I148M liver disease): Clinical planning is underway for the first-in-human study, with a CTA submission on track for 2026.
WVE-N531 (DMD program): The company plans to submit an IND in 2026 for accelerated approval of N531 with a monthly dosing regimen.
WVE-003 (HD program): The company is preparing for a global Phase II/III study using caudate volume as a primary endpoint and plans to submit an IND application in the second half of 2026.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Have you looked into what happens to all the fat that's mobilized post activin E knockdown? Specifically, have you checked the liver fat deposits or looked at lipid panels for any LDL or triglycerides in these mice?
A:Preclinically, no changes in increased lipids and deposits in the liver were observed in DIO studies or preclinical toxicology studies. Clinical genetics show decreased risk of NASH and liver disease in patients. Lipolysis breaks up free fatty acids used as energy, with no concerns noted.
Q:On Huntington's, have you had a pre-IND meeting with the FDA? Any changes to their comments on the use of MRI as a reasonable surrogate for Huntington's?
A:The company has alignment with the FDA on using MRI as an imaging endpoint in connection with other clinical data. They are running a placebo-controlled study and have not observed changes in the FDA's stance. Small changes in caudate atrophy can significantly delay clinical disability.
Q:How variable is the caudate volume within the same Huntington's stage, like Stage 2 and Stage 3?
A:There are steady changes in caudate volume, and caudate is now a core component of staging criteria. Larger caudate volumes at the beginning of studies could delay clinical progression. The company has seen substantial reductions in mutant Huntington and remains confident in their allele-specific approach.
Q:What kind of changes in biomarkers related to metabolism, inflammation, and fibrosis would you like to see by the time you report initial data in the fourth quarter?
A:The company expects rapid engagement of the target and sustained suppression of protein, driving lipolysis. They will track various biomarkers of metabolic health but have not disclosed specific circulating biomarkers they will examine.
Q:Based on your preclinical study, when do you think the weight loss can plateau with 007?
A:The study suggests that weight loss driven by fat does not plateau like GLP-1s. The company will assess the curve over time, with the study designed to evaluate this.
Q:What are your thoughts on DNA editor ATD programs and their ability to reduce M-AAT?
A:The company believes RNA editing offers advantages over DNA editing, such as no off-target edits and infrequent sub-Q administration. They emphasize the importance of achieving MZ phenotype levels and addressing acute exacerbations in alpha-1 antitrypsin deficiency.
Q:Is there a change in plans for the additional exon skipping program for DMD?
A:There is no fundamental change. The company is focusing on advancing exon 53 while being prudent with capital allocation for other programs.
Q:Are you able to gather more examples of acute phase response in the AATD study?
A:The company can identify acute phase responses through CRP levels but is not changing the protocol design. They are encouraged by the basal level response observed in the study.
Q:What proportion of the INLIGHT study is enrolled in the U.S. versus ex-U.S.?
A:The study started ex-U.S., and the U.S. sites are now recruiting at the highest dose (600 mg). Inclusion criteria remain consistent across regions.
Q:On the single AATD patient that experienced the acute phase response, are there any additional insights?
A:The patient recovered, and the response was consistent with an MZ phenotype. No new insights were provided.
Q:Have you optimized the bifunctional single nucleotide construct to avoid intermolecular interference?
A:The platform is designed to be highly specific for both enzymes, with no observed steric hindrance or off-target edits.
Q:What are your thoughts on Sarepta's exon skippers failing to confirm benefit in confirmatory studies?
A:The company emphasizes the importance of consistent dystrophin expression and clinical meaningful responses. They have not observed changes in the FDA's stance on dystrophin as an endpoint.
Q:What is your view on the pricing dynamic in the obesity market?
A:The company believes their approach with INHBE, offering infrequent dosing and accessibility, is highly disruptive. They see an opportunity to address the global obesity market with a once or twice a year sub-Q therapy.
Q:What are the kinetics of weight loss in the obesity program?
A:The company expects slower kinetics compared to semaglutide but anticipates substantial fat loss over time. Human genetics and preclinical models support the potential for sustained weight loss.
Q:What are the next steps in development for the obesity program beyond the INLIGHT study?
A:The company plans to initiate studies in obese patient populations and maintenance therapies. They are open to strategic partnerships but are committed to advancing the program independently if needed.
Q:Have you had any interactions with the FDA on your 48-week DMD data?
A:The company has discussed their plans with the FDA and believes they have enough data to support a filing, including monthly dosing data.
Q:Would you move the Huntington's program forward independently without a partner?
A:The company prefers to progress the program alongside a collaborator to ensure alignment on trial design and regulatory requirements.
Q:Are you expecting to see the placebo-adjusted benchmark for weight loss in the upcoming 3-month data for the 240 mg cohort?
A:The company is not guiding to a specific target for the 3-month data but is focusing on engagement, durability, and biomarkers. They are anchoring on the 6-month data for substantial weight loss.
Q:What is the consideration for initiating the Cohort 5 in the INHBE study?
A:The company is assessing the utility of higher doses beyond 600 mg based on biomarker data and safety. They are confident in their current coverage and planning subsequent studies.
Q:Do you expect any difficulties with the FDA's attitude towards dystrophin expression as an endpoint for DMD?
A:The company has not observed changes in the FDA's stance on dystrophin expression and emphasizes the importance of clinical meaningful responses.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on certain circulating biomarkers they plan to examine in the obesity program. Additionally, they did not clarify the exact kinetics of weight loss expected in the 3-month data for the 240 mg cohort, focusing instead on the 6-month data.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AAT decrease
AAT level
DIO mouse
GalNAc RNA
II III
IV augmentation
PNPLA liver
RNA candidate
Research Day
WVE GalNAc
ZZ
activin reduction
ballooning fibrosis
cessation GLP
cohort month
cohort reduction
compensation
contrast
decrease AAT
disease Europe
excitement
gain cessation
inflammation ballooning
level micromolar
lipid
loss semaglutide
milligram participant
month milligram
opinion leader
rebound weight
reduction milligram
reduction month
serum AAT
steatosis inflammation
track IND
weight gain
WVE Transcript
Wave Life Sciences Ltd. (WVE) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Neutral6-8
Wave Life Sciences Ltd. (WVE) Q4 2025 Earnings Call Transcript
Unknown2-26
The earnings call summary reveals a mixed sentiment. While there are positive developments in product pipeline and strategic alignment with regulatory pathways, the lack of clear guidance on key metrics like fat loss and biomarker data, coupled with management's avoidance of direct answers, creates uncertainty. The Q&A section highlights cautious optimism but also reveals potential risks and uncertainties. Without a market cap context, it's challenging to predict a strong movement, thus a neutral stance is appropriate.
Wave Life Sciences Ltd. (WVE) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-13
Wave Life Sciences Ltd. (WVE) Q3 2025 Earnings Call Transcript
Unknown11-10
The earnings call summary indicates a mix of positive and cautious elements. While there are promising developments in product pipelines and strategic plans, there are also uncertainties, particularly in the obesity program and AATD study. The Q&A highlighted management's avoidance of specifics, which may raise concerns. No strong catalysts like partnerships or record revenues were mentioned, and the strategic plan lacks immediate financial impact. The absence of market cap data limits assessment of stock sensitivity, but overall sentiment leans towards neutral given the balanced positives and uncertainties.
WVE Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
